title: Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
abstract: Down-regulation of copper transporter 1 (CTR1) reduces uptake and sensitivity, whereas down-regulation of CTR2 enhances both. Cisplatin (DDP) triggers the rapid degradation of CTR1 and thus limits its own accumulation. We sought to determine the effect of DDP and copper on the expression of CTR2. Changes in CTR1 and CTR2 mRNA and protein levels in human ovarian carcinoma 2008 cells and ATOX1(+/+) and ATOX1(-/-) mouse embryo fibroblasts in response to exposure to DDP and copper were measured by quantitative reverse transcriptase-polymerase chain reaction, Western blot analysis, and deconvolution microscopy. DDP triggered rapid degradation of CTR1 in 2008 human ovarian cancer cells. However, it increased the expression of CTR2 mRNA and protein levels. Expression of CTR2 was heavily modulated by changes in intracellular copper concentration; copper depletion produced rapid disappearance of CTR2, whereas excess copper increased the level of CTR2 protein. This increase was associated with an increase in CTR2 mRNA and prolongation of the CTR2 half-life. Consistent with prior observations that short hairpin RNA interference-mediated knockdown of CTR2 enhanced DDP uptake and tumor cell kill, reduction of CTR2 by copper starvation also enhanced DDP uptake and cytotoxicity. Comparison of the ability of copper and DDP to modulate the expression of CTR1 in ATOX1(+/+) and ATOX1(-/-) indicated that ATOX1 participates in the regulation of CTR2 expression. Unlike CTR1, the expression of CTR2 is increased rather than decreased by DDP. Therefore, these two copper transporters have opposite effects on DDP sensitivity. CTR2 expression is regulated by copper availability via the copper-dependent regulator ATOX1.
authors.affiliation: Moores Cancer Center, Department of Medicine, University of California, La Jolla, CA 92093-0819, USA.
authors.forename: Brian G
authors.initials: BG
authors.lastname: Blair
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Larson
authors.forename: Preston L
authors.initials: PL
authors.lastname: Adams
authors.forename: Paolo B
authors.initials: PB
authors.lastname: Abada
authors.forename: Roohangiz
authors.initials: R
authors.lastname: Safaei
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Howell
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D027682:Cation Transport Proteins / Q000494:pharmacology* / Q000502:physiology; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002945:Cisplatin / Q000494:pharmacology*; D003300:Copper / Q000494:pharmacology*; D000079922:Copper Transport Proteins; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D056511:Metallochaperones; D051379:Mice; D018832:Molecular Chaperones / Q000502:physiology; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000080083:SLC31 Proteins
chemical_list: C474500:ATOX1 protein, human; D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D000079922:Copper Transport Proteins; D056511:Metallochaperones; D018832:Molecular Chaperones; D000080083:SLC31 Proteins; C524078:SLC31A2 protein, human; D003300:Copper; D002945:Cisplatin